Does the Use of BioZorb® Result in Smaller Breast Seroma Volume?

Abstract

AIM:

To evaluate the impact of BioZorb®, a 3D-bioabsorbable marker, on the tumor-bed boost volume and dosimetric parameters in adaptive boost planning for breast cancer.

PATIENTS AND METHODS:

Records were reviewed for 51 breast-cancer patients who underwent breast-conserving surgery and adjuvant whole-breast irradiation between January 2017 and October 2018. Changes in lumpectomy boost volume (LBV), doses to organs at risk, toxicity and cosmesis were compared between patients with and without BioZorb® Chi-square test and paired and independent t-tests were used for comparisons of variables.

RESULTS:

Median follow-up was 35.5 months. Mean LBV on initial CT (LBV1; 32.2 vs. 33.8 cc, p=0.74) and on boost computed tomography (CT) (LBV2; 25.3 vs. 24.8 cc, p=0.87) were similar with and without BioZorb® The mean decrease from LBV1 to LBV2 was 9.0 cc and 6.8 cc with and without BioZorb®, respectively (p=0.42). LBV1 was significantly positively correlated with a 20% reduction in LBV (p=0.02). Mean heart and lung doses on adaptive boost planning CT were slightly lower compared to initial planning CT in both groups. Acute breast pain was reported in 18/51 patients, 9 of whom had BioZorb® (p=0.24). Grade-2 pain was reported in 5/51 patients, 3 of whom had BioZorb® (p=0.11). Excellent or good cosmesis was reported in 36/41 patients. Fair cosmesis was reported in 5/41 patients, of whom 2 had BioZorb® (p=0.64).

CONCLUSION:

BioZorb® placement does not impact the tumor-bed boost volume nor the variation of seroma volume within the period of treatment. More data and longer follow-up are needed to identify a measurable clinical impact of BioZorb® placement.

• Authors: Zeinab Abou Yehia, Jennifer Yoon, Mutlay Sayan, Shicha Kumar, Lara Hathout, Maria Kowzun, Lindsay Potdevin, Mridula George, Bruce G Haffty, Nisha Ohri
• Journal: Anticancer research (Anticancer Res) Vol. 42 Issue 6 Pg. 2961-2965 (Jun 2022) ISSN: 1791-7530 [Electronic] Greece
• PMID: 35641254 (Publication Type: Journal Article)
• Copyright: Copyright © 2022 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Topics

• Breast Neoplasms (radiotherapy, surgery)
• Female
• Humans
• Lung
• Mastectomy, Segmental (adverse effects)
• Seroma (diagnostic imaging, etiology)
• Tomography, X-Ray Computed